Bobbie Rimel, MD
Gynecologic Oncology · Seattle, WANPI 1770776288
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $31,460 of the $40,969 with a category attached, or 76.8%. 11 manufacturers reported payments, led by AstraZeneca at 37.6% of the total. Reporting peaked in 2019 at $11,578 and has fallen 77.7% since, to $2,581 in 2025. Among gynecologic oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $569.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- GSK$12K
- Merck$5K
- AbbVie$3K
- Intuitive Surgical$2K
- Tesaro, Inc.$2K
- plus $2K from 5 others
Across 123 payments — averaging $9447.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$295K
- Tesaro, Inc.$263K
- Sumitomo Pharma America, Inc.$152K
- Pfizer$147K
- Astrazeneca UK Limited$136K
- AstraZeneca$130K
- plus $38K from 2 others
What the payments were for
- Consulting fees$31,46077%
- Speaking & faculty fees$4,00010%
- Travel & lodging$1,2413%
- Food & beverage$2,9587%
- Education$1,3103%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $15,412 |
| GSK | 18 | $11,689 |
| Merck | 7 | $5,271 |
| AbbVie | 7 | $2,549 |
| Intuitive Surgical | 13 | $2,492 |
| Tesaro, Inc. | 4 | $1,935 |
| Genentech USA, Inc. | 2 | $1,093 |
| Clovis Oncology, Inc. | 2 | $289 |
| Immunogen, Inc. | 1 | $115 |
| Aadi Bioscience, Inc. | 1 | $100 |
| Seagen Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$14,986
- JEMPERLI$3,600
- Elahere$2,359
- ZEJULA$1,895
- Da Vinci Surgical System$1,185
- Avastin$1,040
- TECENTRIQ$1,040
- DAVINCI XI$1,000
- Rubraca$142
- KEYTRUDA$115
How this compares
$40,969 in reported general payments places this provider in the 90th percentile of 36 gynecologic oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 18 | $206 |
| Ondansetron Hcl | 16 | $112 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Seattle
- Chirag ShahSeattle$732K
- Fernanda MusaSeattle$120K
- Nicole FlemingSeattle$20K
- Renata UrbanSeattle$7K
- Amy BrockmeyerSeattle$4K
- Amy BondurantSeattle$2K
- Kathryn PenningtonSeattle$2K
- Soledad JorgeSeattle$1K
- Elise SimonsSeattle$459
- Allison BarrieSeattle$428
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.